Tech Company Financing Transactions
Confluence Life Sciences Funding Round
BioGenerator, Epidarex Capital and Mercury Fund participated in a funding round for Confluence Life Sciences. The round was recorded on 2/20/2014.
Transaction Overview
Company Name
Announced On
2/20/2014
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
Epidarex Capital's financing will support Confluence's identification and development of its lead drug candidates.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4320 Forest Park Avenue
St. Louis, MO 63108
USA
St. Louis, MO 63108
USA
Phone
Email Address
Overview
Confluence Life Sciences is focused on rational drug designs to develop novel kinase inhibitors for use in human and animal healthcare.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Walter Smith
Chief Scientific Officer
Joseph Monahan
Controller
Jennifer Bohnert
Browse more venture capital transactions:
Prev: 2/20/2014: GigaOmniMedia venture capital transaction
Next: 2/20/2014: Solar Mosaic venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs